[go: up one dir, main page]

IL160600A0 - Use of polysubstituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity - Google Patents

Use of polysubstituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity

Info

Publication number
IL160600A0
IL160600A0 IL16060002A IL16060002A IL160600A0 IL 160600 A0 IL160600 A0 IL 160600A0 IL 16060002 A IL16060002 A IL 16060002A IL 16060002 A IL16060002 A IL 16060002A IL 160600 A0 IL160600 A0 IL 160600A0
Authority
IL
Israel
Prior art keywords
prophylaxis
obesity
medicaments
preparation
systems
Prior art date
Application number
IL16060002A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL160600A0 publication Critical patent/IL160600A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16060002A 2001-08-31 2002-08-17 Use of polysubstituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity IL160600A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10142659A DE10142659A1 (de) 2001-08-31 2001-08-31 Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
PCT/EP2002/009200 WO2003020255A1 (de) 2001-08-31 2002-08-17 Verwendung von mehrfach substituierten indan-1-ol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas

Publications (1)

Publication Number Publication Date
IL160600A0 true IL160600A0 (en) 2004-07-25

Family

ID=7697230

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16060002A IL160600A0 (en) 2001-08-31 2002-08-17 Use of polysubstituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity

Country Status (10)

Country Link
US (3) US6686397B2 (es)
EP (1) EP1425000B1 (es)
JP (1) JP2005507382A (es)
AU (1) AU2002333447B2 (es)
CA (1) CA2458553A1 (es)
DE (1) DE10142659A1 (es)
IL (1) IL160600A0 (es)
MX (1) MXPA04001847A (es)
PE (1) PE20030363A1 (es)
WO (1) WO2003020255A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142663B4 (de) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-ol-Systeme
DE10142661B4 (de) * 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
JP4774763B2 (ja) * 2004-03-25 2011-09-14 住友化学株式会社 精製酢酸３−メチル−２−ブテニルの製造方法
US20050257715A1 (en) * 2004-04-08 2005-11-24 Christophe Dumousseaux Compositions for application to the skin, to the lips, to the nails, and/or to hair
US20050238979A1 (en) * 2004-04-08 2005-10-27 Christophe Dumousseaux Compositions for application to the skin, to the lips, to the nails, and/or to hair
US9649261B2 (en) 2004-10-05 2017-05-16 L'oreal Method of applying makeup to a surface and a kit for implementing such a method
FR2876011B1 (fr) * 2004-10-05 2006-12-29 Oreal Procede de maquillage d'un support et kit pour la mise en oeuvre de ce procede
ES2333241T3 (es) * 2004-10-05 2010-02-18 L'oreal Kit y procedimiento de maquillaje.
KR100693528B1 (ko) * 2004-10-29 2007-03-14 주식회사 팬택 전원 지연 인가 기능을 가지는 무선통신 단말기
FR2888115B1 (fr) * 2005-07-08 2013-02-15 Oreal Fond de teint liquide, procede de maquillage et kit pour la mise en oeuvre d'un tel procede.
FR2889921B1 (fr) 2005-08-30 2007-12-28 Oreal Ensemble de conditionnement et d'application comportant un dispositif magnetique.
DE102013009631A1 (de) * 2013-06-10 2014-12-11 Forschungszentrum Jülich GmbH Verfahren zur Herstellung von Cathin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2345146C3 (de) 1973-09-07 1981-08-06 Feinmechanische Werke Mainz Gmbh, 6500 Mainz Hydraulischer Stellantrieb
FR2345146A1 (fr) * 1976-03-23 1977-10-21 Logeais Labor Jacques Nouveau medicament a base d'(hydroxy-2 indanyl-2) 1-propanol
DE2965279D1 (en) * 1978-07-27 1983-06-01 Schering Ag Indanyl derivatives, process for their preparation and pharmaceutical compositions containing these compounds
DE3103372A1 (de) * 1981-01-27 1982-09-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue indanyl-derivate, ihre herstellung und verwendung
CA2239694C (en) * 1995-12-06 2008-05-06 Venantius Limited Indane dimer compounds and their pharmaceutical use
IL125071A0 (en) 1996-01-17 1999-01-26 Novo Nordisk As Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives their preparation and use
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
JP4339402B2 (ja) 1996-12-31 2009-10-07 ドクター・レディーズ・ラボラトリーズ・リミテッド 新規なヘテロ環化合物、これらの製造方法及びこれらを含有する薬学的組成物、並びに糖尿病及び関連疾患の治療におけるこれらの使用
CA2294830A1 (en) 1997-07-16 1999-01-28 John Bondo Hansen Fused 1,2,4-thiadiazine derivatives, their preparation and use
US5987946A (en) 1997-08-15 1999-11-23 Watts; James A. Lock picking method and apparatus
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
AU781003B2 (en) * 2000-02-23 2005-04-28 Aventis Pharma Deutschland Gmbh 8,8A-dihydro-indeno(1,2-D)thiazole derivatives, substituted in position 8A, a method for their production and their use as medicaments, e.g. anorectic agents
DE10142661B4 (de) * 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
DE10142662B4 (de) * 2001-08-31 2004-07-08 Aventis Pharma Deutschland Gmbh Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
US20030130323A1 (en) 2003-07-10
CA2458553A1 (en) 2003-03-13
EP1425000A1 (de) 2004-06-09
PE20030363A1 (es) 2003-06-09
US6812257B2 (en) 2004-11-02
JP2005507382A (ja) 2005-03-17
DE10142659A1 (de) 2003-03-20
US20040092488A1 (en) 2004-05-13
EP1425000B1 (de) 2012-08-01
US20040106583A1 (en) 2004-06-03
AU2002333447B2 (en) 2006-10-26
MXPA04001847A (es) 2004-06-15
US6812256B2 (en) 2004-11-02
WO2003020255A1 (de) 2003-03-13
US6686397B2 (en) 2004-02-03

Similar Documents

Publication Publication Date Title
IL160524A0 (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
IL160187A0 (en) Aerosolized decongestants for the treatment of sinusitis
HUP0401192A3 (en) Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds
IL158590A0 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
AU2003300791A1 (en) Combination therapy for the treatment of pain
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
IL160600A0 (en) Use of polysubstituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
AU2002333447A1 (en) Use of polysubstituted indan-1-ol systems for producing drugs in the prophylaxis or treatment of obesity
AU2002364171A1 (en) Materials and methods for the treatment or prevention of obesity
IL157065A0 (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
AU2002236781A1 (en) Treatment for snoring
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
IL178903A0 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
AU2002342615A1 (en) Use of derivatives of C2-substituted indan-1-ol systems for producing medicaments for the prophylaxis or the treatment of obesity
AU2002336984A1 (en) Use of C2-substituted Indane-1-ol systems for producing medicaments for the prophylaxis or treatment of obesity
IL160607A0 (en) Use of c2-substituted indan-1-one systems for preparing medicaments for the prophylaxis or treatment of obesity
AU2002336985A1 (en) Use of C2-substituted Indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i